Q2 2026 Immunovia AB (publ) Earnings Call Transcript
Key Points
- Immunovia AB (LTS:0G8X) achieved a significant milestone with 27 high-risk surveillance programs using PancreaSure since launch, including 10 of the top 20 US cancer centers, such as Memorial Sloan Kettering.
- Net sales increased by over 300% in Q2 2026 to SEK381,000 compared to the same period last year, with first-half sales reaching SEK755,000.
- The company is on track to submit for Medicare coverage in Q3 2026, supported by strong pooled analysis data showing 83.3% sensitivity and 92% specificity in the high-risk symptomatic population.
- The sales pipeline has expanded significantly, growing from 71 engaged prospective centers in Q1 to over 110 centers in Q2, indicating strong market interest.
- Immunovia AB (LTS:0G8X) is actively pursuing multiple business development opportunities, including partnerships with large US diagnostics companies, multi-cancer early detection test developers, and pharmaceutical companies, as well as expansion into Asian markets like Japan and China.
- The company's cash burn was lower than expected at SEK7 million per month, below the guidance of SEK8-10 million, extending the runway into Q4 2026.
- Immunovia AB (LTS:0G8X) continues to report significant operating losses, with an operating loss of SEK22.9 million in Q2 2026 and SEK41.3 million for the first half of the year.
- The company's cash position is limited at SEK34.9 million, only funding operations into Q4 2026, requiring active evaluation of equity financing or partnerships to extend the runway to 2027.
- Revenue generation remains minimal due to the lack of established reimbursement, with the company still awaiting early results from commercial insurers submitted in February 2026.
- The timeline for Medicare coverage decisions is uncertain and could vary significantly, with no hard and fast timeline provided, potentially delaying full revenue potential.
- The transition from trial use to full adoption at customer sites faces challenges, including the need to modify existing protocols and processes at health systems, which can slow volume growth.
- The company is still awaiting approval from New York State, which is critical for market access in one of the largest US states, with no guaranteed timeline for a decision.
()- -
Thank you very much, and thank you to all of you for joining us today for the review of Immunovia's second quarter of 2026. As we will share, we have achieved important milestones in the commercialization of PancreaSure, and we are transitioning to the second phase of the PancreaSure test launch.
We're also excited about the progress that we continue to make in the pursuit of Medicare coverage, and we'll share updates on our efforts there. I'm also pleased with our business development progress as we have ongoing conversations with potential partners. As you can imagine, I won't be able to share a lot about the specifics of those opportunities, but wanted you to know that we are focused on business development and are pursuing a number of paths there.
So for today's call, we will focus initially on the commercial uptake and traction of the PancreaSure test. We'll also talk a little bit about some of the drivers of growth in the second half of the year. My colleague, Adam,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
